Tirzepatide

A once-weekly compounded tirzepatide protocol, prescribed when clinically appropriate for adults evaluating long-term metabolic care via dual GIP/GLP-1 receptor activation.

503A · CompoundedPhysician-reviewedU.S. pharmacy

Your Plan Options

Weekly injection

4-week plan

$339 /4 wk

Weekly injection

12-week plan

$927 /12 wk

Weekly injection

24-week plan

$1,734 /24 wk

Weekly injection

52-week plan

$3,497 /52 wk

Begin your consultation

No charge until a provider prescribes. Prescription required.

Clinical information

What this is, in plain language.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. The compounded preparation is prepared by a licensed 503A compounding pharmacy and dispensed only when a licensed provider determines it is clinically appropriate. It is administered as a once-weekly subcutaneous injection, with dosing titrated under clinical guidance.

Active ingredients

Tirzepatide.

Mechanism

Dual GIP/GLP-1 receptor agonist. Activates two incretin pathways for enhanced metabolic response.

Administration

Once-weekly subcutaneous injection. Titrated under clinical guidance.

Who it is for

Adults evaluating dual-pathway metabolic care, when clinically appropriate.

Common effects

Nausea, reduced appetite, injection-site reactions. Discuss full risks with your provider.

Important safety & compliance information

Compounded tirzepatide is not FDA-approved. It is prepared by a licensed 503A compounding pharmacy and is descriptive only — it is not a branded drug. Product imagery shown here is illustration only; actual medication is dispensed in a pharmacy-labeled container and will vary in appearance. A prescription is required and is issued only when a licensed provider determines treatment is clinically appropriate. This page is not medical advice. Discuss benefits, risks and side effects with your provider.